The Instituto de Oncología Intervencionista (IDOI México) is a multidisciplinary oncology team that treats DIPG and various other types of cancers with novel and multimodal approaches to the disease, improving the patient’s survival and quality of life.
IDOI’s unrestrained model of treatment is individualized to the patient’s particular needs. Which is exactly the reason why IDOI was born in the first place.
Understanding DIPG: Know the enemy
Diffuse intrinsic pontine glioma is a highly aggressive tumor in the pons with a historic poor prognostic that affects mostly children, from around the world.
The brainstem is divided into 3 major areas—midbrain, PONS, and medulla—and different types of tumors can occur in any of these locations.
A GLIOMA is a tumor that arises from a cell in the brain called a glial cell (support cells for the neurons). One type of glioma is called an astrocytoma, which is a tumor that arises from a specific type of glial cell called an astrocyte. The two major types of astrocytomas are pilocytic astrocytomas and diffuse, infiltrating astrocytomas. The term DIPG specifically refers to a diffuse, infiltrating astrocytoma that develops in the pons.
The last decade studies focused their efforts on ideal monotherapies to attack diverse pathways with different levels of success but no clear cure so far. In the meantime, hundreds of families rush looking for any hope. However, most of the patients won’t survive a year trying their hardest with the scarce tools that their oncologists have at their disposal. Systemic chemotherapy resulting mostly ineffective; radiotherapy and steroids proving themselves merely palliative while bringing their own set of adverse effects.
This is the precise reason that makes novel therapeutic alternatives a dire and inescapable necessity.
While standard protocols will hopefully bring an adequate treatment or final cure for DIPG in the future, TODAY, individualized and compassionate use programs around the world are the only chance for any improvement to most of the currently afflicted patients.
Perhaps the first step towards a cure, after the creation of research tools such as the SIOPE DIPGR, lie in “out of the norm” attempts, such as IDOI México’s, to do something about DIPG patients in a personalized basis.
According to Hoffman et al., 2018 *, the largest DIPG case study done to date, the “progression of the disease” by RANO criteria was given 6 months after diagnosis with a rapid deterioration. The overall survival of the DIPG patient (50% deceased) is 11 months after diagnosis. Then, at one year, 2 years and 5 years, only 42.3%, 9.6% and 2.2% of patients will still be alive.
The overall survival of the DIPG patient treated by IDOI México is over 20 months. Most regaining quality of life coming from various degrees of progression of the disease.
And as many families have said:
“They (IDOI) are willing to try.”
The Instituto de Oncología Intervencionista (IDOI México - Institute of Interventional Oncology) joins two successful professional careers and two complementary experiences, one focused on Oncology and the other on Interventional Neuroradiology, which has allowed to find new ways of using multiple techniques, procedures, and medications to treat different types of cancer including DIPG.
IDOI México has obtained international recognition thanks to the positive responses in quality of life and improved survival of over 60 DIPG cases from around the world using Super-Selective Intra-Arterial & Intrathecal Chemotherapy (SSIAITC, a minimally invasive procedure).